Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 8, Issue 1, Pages 5-15Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.8.1.5
Keywords
cancer; CD200; immune evasion; immunosuppression; leukemia; monoclonal antibodies
Ask authors/readers for more resources
Immune evasion in cancer is increasingly recognized as a contributing factor in the failure of a natural host antitumor immune response as well as in the failure of cancer vaccine trials. Immune evasion may be the result of a number of factors, including expansion of regulatory T cells, production of immunosuppressive cytokines, clownregulation of HLA class I and tumor-associated antigens and upregulation of immunosuppressive molecules on the surface of tumor cells. CD200, a cell surface ligand that plays a role in regulating the immune system, has been shown to be upregulated on the surface of some hematologic and solid tumor malignancies. This review characterizes the role of CD200 in immune suppression, and describes strategies to target this molecule in the oncology setting, thus directly modulating immune regulation and potentially altering tolerance to tumor antigens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available